As tezepelumab awaits FDA decision, Amgen and AstraZeneca tout more data from the Phase III study
As AstraZeneca and Amgen’s Dupixent challenger awaits a decision by the FDA, the companies are touting new data they hope could bolster their case.
Researchers revealed additional results from a pivotal Phase III trial for AstraZeneca and Amgen’s tezepelumab over the weekend, studying the treatment in severe, uncontrolled asthma. In an exploratory analysis looking at patients with or without reported nasal polyps, tezepelumab showed it can reduce asthma exacerbation by 86% in the former group and 52% in the latter when compared to standard of care.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.